Misopristol
PreclinicalSmall molecule
Misopristol is one of 40 small molecule programs targeting Abortion. It is currently in Preclinical.
2
Indications
2
Total Trials
1
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
40 competitors in Abortion
#DrugCompanyPhaseTrials
1Cytotec
PfizerApproved
Mifeprex
DDanco
Approved
Amidate
PfizerApproved
Xylocaine
MMEDRx USA, Inc.
Approved
Prometrium
FerringApproved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Duragesic
CCephalon
Approved
Ativan
BBausch Health Americas, Inc.
Approved
Imdur
OOmnivium
Approved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Abortion1 trial
Misoprostol in Missed Abortion
Not yet recruiting·—··NCT06818903·122 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Misopristol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SSohag University